Jun 08, 2020
Neurelis Announces Rapid and Broad Payer Coverage of the Company's Flagship Product, VALTOCO® (Diazepam Nasal Spray)
Jun 05, 2020
UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
May 14, 2020
InventHelp Presents a Seizure Warning Device (FLA-3242)
May 04, 2020
Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors
Mar 26, 2020
European Medicines Agency Accepts Arvelle Therapeutics' Marketing Authorization Application for Cenobamate for the Adjunctive Treatment of Focal-Onset Seizures in Adults
Mar 23, 2020
Technological Advancement to Drive Market Players Propel Growth in Epilepsy Therapeutics Market from 2019 to 2027: TMR
Mar 10, 2020
SK life science Receives Schedule V Designation from DEA for XCOPRI® (cenobamate tablets)
Mar 02, 2020
Neurelis Announces Commercial Availability of VALTOCO® (Diazepam Nasal Spray) for Seizure Cluster Rescue
Feb 10, 2020
Global DEE Market Insights, 2017-2028 - Eisai Pharmaceuticals (Fycompa; Perampanel), Zogenix (Fintepla; ZX008), Takeda/Ovid (Soticlestat; TAK-935/OV935), and Zynerba Pharma (Zygel; ZYN002)
Feb 07, 2020
The SPEAC System's sEMG Seizure Monitoring Results To Be Featured at the American Clinical Neurophysiology Society (ACNS) Annual Meeting
Feb 04, 2020
Epilepsy Foundation Florida Announces Launch of the Walk to END EPILEPSY® Miami
Jan 27, 2020
Tuberous Sclerosis Alliance Lauds Lundbeck And FDA For Sabril Label Expansion For Patients 2 To 10 Years Old
Jan 13, 2020
Neurelis Announces FDA Approval for Seizure Rescue Treatment VALTOCO® (Diazepam Nasal Spray) that Incorporates the Science of Intravail® for Consistent and Reliable Absorption
Jan 09, 2020
Mercaptor Discoveries Announces Preclinical Program in Epilepsy
Jan 08, 2020
Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
Jan 07, 2020
Cerebral Therapeutics Completes $35 Million Series B Financing
Dec 09, 2019
Lower Hospitalization Rates Seen Among Epilepsy Patients Treated with FYCOMPA® and Select Anti-Epileptic Drug (AED) Combinations
Dec 09, 2019
Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting
Dec 07, 2019
Mallinckrodt Presents Data on a Novel Predictive Model to Identify Infants at Risk for Infantile Spasms (IS) at the 2019 Annual Meeting of the American Epilepsy Society (AES)
Dec 07, 2019
Ceribell Announces Launch Of Clarity, Providing 24/7 Automatic Bedside Monitoring To Enhance EEG Capability